Mortality rates from most major cancers are predicted to continue falling in Europe and the UK in 2022, with a particularly striking reduction in deaths from ovarian cancer.
An additional 12 months of follow-up confirmed the benefits of the combination therapy as a first-line treatment for advanced or metastatic esophageal cancer.
Patients with non–small cell lung cancer harboring HER2 mutations experienced durable activity and promising survival outcomes with trastuzumab deruxtecan, a new study shows.
Patients who develop upper gastrointestinal cancers within 3 years of esophagogastroduodenoscopy are less likely to present with alarm symptoms than patients whose upper GI cancers are detected at endoscopy, according to new research.
Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study.